New hope for rare leukemia: ABC008 drug trial shows promise

NCT ID NCT05532722

Completed Disease control Sponsor: Abcuro, Inc. Source: ClinicalTrials.gov ↗

First seen May 16, 2026 · Last updated May 20, 2026 · Updated 2 times

Summary

This study tested a new drug called ABC008 in 21 adults with a rare type of blood cancer called T-cell large granular lymphocytic leukemia (T-LGLL). The goal was to check the drug's safety and how it affects blood counts. Participants received increasing doses of the drug to find the best and safest level.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

City of Hope

Duarte, California, 91010, United States
Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Huntsman Cancer Institute, University of Utah

Salt Lake City, Utah, 84112, United States
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
The University of Texas M.D. Anderson Cancer Center

Houston, Texas, 77030, United States
University of Southern California

Los Angeles, California, 90033, United States

Conditions

Explore the condition pages connected to this study.

T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA